Method of improving transplant function using soluble complement receptor type I (sCR1)

US9649356B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9649356-B2
Application numberUS-201113283364-A
CountryUS
Kind codeB2
Filing dateOct 27, 2011
Priority dateOct 27, 2010
Publication dateMay 16, 2017
Grant dateMay 16, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to harvesting the organ for transplant.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for preparing a transplant organ from a brain-dead organ donor to improve organ function in a recipient of said transplanted organ from said brain-dead organ donor, said method comprising administering to a brain-dead mammalian donor an effective amount to inhibit systemic and/or local complement activation of a soluble complement receptor type I (sCR1) polypeptide prior to excision of said organ from said donor. 2. A method for improving transplant organ function in a transplant organ recipient comprising: administering to a brain-dead organ donor an amount of a soluble CR1 polypeptide effective to inhibit systemic and/or local organ donor complement activation; removing an organ from said brain-dead organ donor; and transplanting said organ into a recipient. 3. A method of treating transplant organ rejection in a recipient of a transplant from a brain-dead organ donor, said method comprising administering to said brain-dead mammalian donor an effective amount of a soluble complement receptor type I (sCR1) polypeptide. 4. The method according to any of claims 1 - 3 , wherein said sCR1 polypeptide is selected from the group consisting of a fragment of human CR1 comprising at least short consensus repeats 8-11; a fragment of human CR1 comprising at least short consensus repeats 15-18; a soluble CR1 polypeptide comprising human CR1 short consensus repeats 8-11 and 15-18; a fragment of human CR1 comprising long homologous repeat B; a fragment of human CR1 comprising long homologous repeat C; a fragment of human CR1 comprising long homologous repeats B and C; a fragment of human CR1 comprising long homologous repeats B, C and D; a fragment of human CR1 comprising at least long homologous repeats A and B; a fragment of human CR1 comprising long homologous repeats A, B and C; a fragment of human CR1 comprising long homologous repeats A, B, C and D; a fragment of human CR1 comprising the extracellular domain of CR1; a fragment of human CR1 comprising the extracellular domain of CR1 and having the N-terminal LHR A deleted (sCR1 [desLHR-A]); a soluble CR1 polypeptide having modified glycosylation to improve serum half-life in vivo; a soluble CR1 polypeptide having glycosylation modified to exhibit sialyl Lewis X moieties (sCR1-sLe x ); a soluble CR1 construct having two or more CR1 polypeptide moieties linked to a carrier molecule; and combinations thereof. 5. The method according to claim 4 , wherein said sCR1 polypeptide is administered by an intradermal, intramuscular, intraperitoneal, intravenous, intra-arterial, subcutaneous, intrathecal, epidural, oral or pulmonary route. 6. The method according to claim 5 , wherein said organ is selected from the group consisting of liver, kidney, heart, and lung. 7. The method according to claim 6 , wherein said organ is a kidney.

Assignees

Inventors

Classifications

  • A61K38/177Primary

    Receptors; Cell surface antigens; Cell surface determinants · CPC title

  • Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)} · CPC title

  • Immunosuppressants, e.g. drugs for graft rejection · CPC title

  • Immunomodulators · CPC title

  • Human Necessities · mapped topic

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9649356B2 cover?
A method is disclosed for inhibiting complement activation in brain-dead organ donors, particularly kidney donors, which leads to improvement of organ function of transplanted organs in recipients. The method involves administration of a complement inhibitory protein, specifically a soluble complement receptor type I (sCR1) polypeptide to the donor prior to harvesting the organ for transplant.
Who is the assignee on this patent?
Seelen Marc Antonius, Celldex Therapeutics Inc
What technology area does this patent fall under?
Primary CPC classification A61K38/177. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).